Curaleaf Holdings (CURLF) Cash from Operations (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Cash from Operations of 48107000.0 for Q4 2024, up 251.12% year-on-year from 13701000.0 in Q1 2024, and up 13.54% on a QoQ basis from 42370000.0 in Q3 2024.
Curaleaf Holdings (CURLF) Cash from Operations (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Cash from Operations for 6 consecutive years, with 48107000.0 the latest figure, recorded in Q4 2024.
- Quarterly Cash from Operations rose 251.12% year-over-year to 48107000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 163624000.0 (up 117.41% YoY) and the FY2025 annual result came in at 137706000.0, down 15.84% from the prior year.
- Cash from Operations advanced to 48107000.0 in Q4 2024 per CURLF's latest filing, from 42370000.0 in the prior quarter.
- Over the last five years, Cash from Operations for CURLF reached as high as 43776000000.0 in Q1 2024 and fell as low as 43702853000.0 in Q2 2024.
- A 5-year average of 14463918.75 and a median of 21307500.0 in 2020 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations surged 180648.47% — and 2023, when it slumped 11641.34%.
- Year by year, Cash from Operations stood at 19166000.0 in 2020, then tumbled by 260.88% to 30835000.0 in 2021, then soared by 208.38% to 33418000.0 in 2022, then slumped by 59.0% to 13701000.0 in 2023, then soared by 251.12% to 48107000.0 in 2024.
- According to Business Quant data, Cash from Operations over the past three periods registered 48107000.0, 42370000.0, and 43702853000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 48.11 Mn |
| Dec 31, 2024 | 48.11 Mn |
| Sep 30, 2024 | 42.37 Mn |
| Sep 30, 2024 | 42.37 Mn |
| Jun 30, 2024 | -43.70 Bn |
| Jun 30, 2024 | -43.70 Bn |
| Mar 31, 2024 | 43.78 Bn |
| Mar 31, 2024 | 43.78 Bn |
| Dec 31, 2023 | 13.70 Mn |
| Dec 31, 2023 | 13.70 Mn |
| Sep 30, 2023 | 46.82 Mn |
| Sep 30, 2023 | 46.82 Mn |
| Jun 30, 2023 | -7.88 Bn |
| Jun 30, 2023 | -7.88 Bn |
| Mar 31, 2023 | 7.90 Bn |
| Mar 31, 2023 | 7.90 Bn |
| Dec 31, 2022 | 33.42 Mn |
| Dec 31, 2022 | 33.42 Mn |
| Sep 30, 2022 | 43.98 Mn |
| Sep 30, 2022 | 43.98 Mn |